Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Eisai Co. Ltd.

www.eisai.com

Latest From Eisai Co. Ltd.

Deal Watch: Celgene The Latest To Buy Into Nimbus’ Computational Chemistry Approach

The big biotech takes options on preclinical Tyk2 and STING programs. REGENXBIO drops out of the bidding for Dimension, ceding to Ultragenyx, and Eisai licenses four drugs to Uruguay’s Grupo Biotoscana.

Deals M & A

AmerisourceBergen Oncology Drug Repackaging Program Draws $260m Fine

Now-defunct AmerisourceBergen subsidiary inappropriately repackaged oncology support drugs like Neupogen and Procrit in pre-filled syringes, violating the law and prompting safety concerns, Department of Justice announced.

Compliance Legal Issues

Bristol's Opdivo Diversifies Options In Liver Cancer

Response rate data supports yet another supplemental approval for Opdivo in an underserved tumor type that is becoming more competitive.

Approvals ImmunoOncology

Pipeline Watch: Phase III Readouts For ADV7103, Pembrolizumab, Upadacitinib

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register